Brazil’s drug market regulation chamber (price regulator)
Brazil’s drug market regulation chamber (price regulator)
Bristol Myers Squibb and A.C.Camargo Cancer Center signed BMS’s first oncology risk-sharing agreement in Brazil, covering first-line ipilimumab plus nivolumab in lung cancer, with results assessed within 90 days of …
Anvisa cancelled Elevidys’s conditional registration on August 24 at Roche’s request, citing insufficient safety and efficacy data — ending Brazilian access to the country’s most expensive approved drug.
You must be logged in to post a comment.